Clinical Trial Update: Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2 [Phase 3]

View source ↗

Summary

Phase 3 trial (ARISE-2) evaluating safety and efficacy of RGN-259 ophthalmic solution for Dry Eye Syndrome has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye Syndrome

Drugs mentioned

• RGN-259 ophthalmic solution (RGN-259)

Snippet

Sponsor: ReGenTree, LLC | Conditions: Dry Eye Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2022-01-05